Lilly CEO Breaks From PhRMA, Innovators With Support For CREATES Act
Executive Summary
Legislation that would prevent REMS from blocking generics appears to be gaining momentum.
You may also be interested in...
Reducing Patents Gets Attention From House Freedom Caucus At Pricing Hearing
House Oversight Committee Ranking Member Jim Jordan suggests that Congress may need to re-evaluate the length of pharma patents and FDA exclusivities.
CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor
The Creating and Restoring Equal Access to Equivalent Samples Act clears US Senate Judiciary Committee. During markup, Sens. Hatch, R-Utah, and Cornyn, R-Tex., preview future amendments that would benefit innovators.
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
New draft guidances are an attempt to curb abuse of REMS single shared system process to delay generic entry.